WO2002050307A1 - Procede de detection de polymorphisme dans l'adn au moyen d'une spectroscopie de masse - Google Patents
Procede de detection de polymorphisme dans l'adn au moyen d'une spectroscopie de masse Download PDFInfo
- Publication number
- WO2002050307A1 WO2002050307A1 PCT/JP2001/010892 JP0110892W WO0250307A1 WO 2002050307 A1 WO2002050307 A1 WO 2002050307A1 JP 0110892 W JP0110892 W JP 0110892W WO 0250307 A1 WO0250307 A1 WO 0250307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substrate
- dna
- polymorphism
- oligonucleotide
- site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6872—Methods for sequencing involving mass spectrometry
Definitions
- the present invention relates to a system for efficiently identifying a polymorphism on a genome using mass spectrometry.
- genomic base sequence information With the development of genome analysis technology, the nucleotide sequence of the entire human genome is now being determined. Furthermore, determination of differences in genomic base sequences of individuals, that is, genetic polymorphisms, using the determined genomic base sequence information has been actively performed. Genetic polymorphism determination has become one of the most important issues in the medical and diagnostic fields in recent years because it enables the identification of disease-related genes, disease-causing genes, and eventually drug discovery target genes.
- PCR-RFLP Restriction Fragment Length Polymorphism
- This method is based on the principle that after a reaction amplified by PCR with a base sequence-specific restriction enzyme, the presence or absence of cleavage due to a difference in base sequence is detected as a difference in molecular weight by electrophoresis.
- restriction enzyme that specifically recognizes the polymorphic site, and the restriction enzyme used differs depending on the target SNPs. There is a problem that is not.
- PCR-Single-Strand Conformation Polymorphism has also been used to detect genetic polymorphisms.
- SSPC PCR-Single-Strand Conformation Polymorphism
- SNP single nucleotide polymorphism
- the present inventors have conducted intensive research to solve the above-mentioned problems.
- an oligonucleotide capable of hybridizing with genomic DNA containing the target polymorphism is bound to a substrate, and a genomic DNA sample is applied to the substrate. It has been found that genomic DNA containing the target polymorphism can be selected from the DNA sample on the substrate and can be complemented to the substrate, and thereby the target polymorphism can be detected efficiently.
- genomic DNA containing the target polymorphism was selected in advance, and this was directly applied to a substrate to detect the polymorphism. Needed.
- the oligonucleotide capable of hybridizing with the genomic DNA containing the target polymorphism is bound to the substrate, DNA other than the genomic MA containing the target polymorphism in the DNA sample is used. Even if the DNA is contained, the target DNA can be selected on the substrate by the hybridization reaction, and at the same time, the DN is added to the substrate. A can be supplemented.
- the method of the present invention it is not necessary to select genomic DNA containing the polymorphism in advance and apply it to the substrate, and it is possible to efficiently detect the polymorphism. This is especially true when detecting polymorphisms in a large number of samples, for example, when determining genetic polymorphism variations comprehensively in a sample population of several hundred people to several thousand people, or for certain disease groups. This is effective when identifying one genetic marker (for example, polymorphic microsatellite) required for disease correlation analysis.
- one genetic marker for example, polymorphic microsatellite
- DNAs containing the target polymorphisms are selected by utilizing a hybridization reaction on a substrate. Provides a way to make supplements.
- the present invention provides
- the DNA sample in step (a) is: (i) a pair of primers designed to sandwich a polymorphic site, at least one of which is a primer pair containing a site that can be specifically cleaved; (Ii) cleaving the amplified product obtained at the site where it can be specifically cleaved, using (iii) ) Adding any DNA to the amplified product after the cleavage, and obtaining the oligonucleotide in step (b).
- the method according to (1), wherein the peptide is an oligonucleotide capable of specifically hybridizing to the arbitrary DNA.
- a DNA sample containing a polymorphic site and its neighboring region has been prepared targeting polymorphic sites at a plurality of different loci of the same person, and the DNA sample has been immobilized on the same substrate.
- a DNA sample containing a polymorphic site and its neighboring region is prepared by targeting a polymorphic site at the same locus of a plurality of persons, and the DNA sample is transferred to an oligo- immobilized on the same substrate.
- a DNA sample containing a polymorphic site and its neighboring region which is a substrate for use in the method according to (7) and is prepared by targeting a polymorphic site in the same gene locus of a plurality of persons.
- Substrate on which an oligonucleotide fragment capable of hybridizing to the substrate is immobilized,
- the present invention in the method of the c the present invention to provide a method for detecting a polymorphism of MA using a mass spectrometer effectively, firstly, a polymorphic site from the subject a DNA specimen including the neighboring region Prepare (step (a)).
- the polymorphism that can be detected in the method of the present invention.
- examples of the polymorphism include single nucleotide substitution polymorphism (SNP) and microsatellite, but microsatellite is particularly suitable for correlation analysis targeting a large genome region. If microsatellite is used to perform correlation analysis covering the entire human genomic region, the purpose can be achieved if approximately 30,000 microsatellites can be used. In the case of, about several hundred thousand places are considered necessary. Therefore, when performing a correlation analysis targeting a vast genomic region using the method of the present invention, targeting microsatellite is more effective in reducing the number of polymorphisms required for detection. This is preferable because the reduction can be achieved.
- SNP single nucleotide substitution polymorphism
- microsatellite is particularly suitable for correlation analysis targeting a large genome region. If microsatellite is used to perform correlation analysis covering the entire human genomic region, the purpose can be achieved if approximately 30,000 microsatellites can be used. In the case of
- the ⁇ A sample containing the polymorphic site and its neighboring region can be prepared from a subject, for example, as follows. That is, first, a microsatellite repetitive sequence is detected from a human genome sequence by a computer, and a primer is set so that the chain length of the unit duplication sequence (amp 1 icon) is 200 bp to 300 bp across the repetitive sequence. Then, a genomic DNA of the subject is subjected to PCR using the primers set as described above to obtain a DNA sample of a desired size.
- near region of the polymorphic site in the present invention you adjacent to the polymorphic site on the genomic DNA polymorphism of 5 5 and 3 refers to a DNA region side.
- the size of a DNA fragment that can be analyzed using a mass spectrometer generally ranges from 200 bp to 300 bp. Therefore, in the present invention, The “region near the polymorphic site” to be subjected to gene amplification by setting a marker is usually within 300 bp, preferably within 200 bp from the polymorphic site.
- the DNA sample is hybridized to an oligonucleotide fragment immobilized on a substrate, the oligonucleotide fragment being capable of specifically hybridizing with the DNA containing the target polymorphism (step ( b)) c
- DNA containing the target polymorphism is selected from the DNA sample and is simultaneously captured on the substrate. Therefore, labor and time are remarkably reduced as compared with the conventional method in which DNA containing the target polymorphism is prepared and applied in advance. This is particularly remarkable when detecting polymorphism in a large amount of sample.
- DNAs corresponding to respective oligonucleotides are sorted on a substrate. Therefore, it is possible to distinguish which polymorphism the DNA corresponds to, based on the hybridizing position. This makes it possible to rapidly and comprehensively detect polymorphisms in a large number of samples.
- the “substrate” is not particularly limited as long as it can immobilize an oligonucleotide, but is preferably a plate-like material.
- a substrate having conductivity for ionizing the DNA to be detected is used as the substrate to which the oligonucleotide is bound.
- the substrate is not particularly limited as long as it has conductivity.
- a glass plate fixed to a conductive plate can be suitably used in the present invention.
- a preferred conductive plate for example, a stainless steel plate can be exemplified.
- the glass plate is preferably a glass plate coated with a polycarbonate substrate or the like.
- the oligonucleotide immobilized on the substrate is not particularly limited as long as it is an oligonucleotide fragment capable of specifically hybridizing with the DNA containing the target polymorphism.
- “specifically hybridizing I” refers to the DNA containing the target polymorphism in the DNA sample. It means that it hybridizes substantially and does not substantially hybridize with other DNA.
- the oligonucleotide preferably has a base sequence capable of specifically hybridizing with the base sequence in the vicinity region of the polymorphism to be detected. If specific hybridization is possible, it does not need to be completely complementary to the nucleotide sequence in the vicinity of the polymorphism to be detected.
- the number of oligonucleotides immobilized on the substrate need not be limited to one, but may be a mixture of a plurality of types of oligonucleotides having complementarity in the region of the genomic fragment to be identified.
- the oligonucleotide immobilized on the substrate can be designed so as to obtain genetic information from the same individual. For example, to identify polymorphisms in the same person's microsatellite, oligonucleotides targeting one or more polymorphic sites (for example, 10,000 to 30,000 sites) can be identified by one or more substrates. Can be fixed on top and used as one set.
- oligonucleotides By simultaneously applying and hybridizing a DNA sample prepared from a subject to multiple types of oligonucleotides on the same substrate, it is possible to rapidly and comprehensively detect multiple polymorphisms of the same person. It becomes possible. Therefore, for example, by binding oligonucleotides targeting multiple polymorphisms related to multiple diseases on a substrate, it is possible to easily detect a disease that may or may cause a subject to become ill. Such substrates are particularly useful in genetic diagnostics because they can be identified.
- the same oligonucleotide is bound to the substrate as a plurality of dots, whereby the genetic information of a plurality of sample populations relating to a specific polymorphism can be obtained quickly and comprehensively. it can.
- Such an embodiment is particularly effective for performing disease correlation analysis using genetic polymorphism (for example, microsatellite II SNP).
- the DNA sample is prepared by using (I) a primer pair designed to sandwich the polymorphic site, wherein at least one of the primer pairs contains a site that can be specifically cleaved. Subjecting the subject's genomic DNA to a type I polymerase chain reaction, (ii) cutting the resulting amplification product at the site that can be specifically cleaved, and (iii) It can be obtained by adding any DNA to the amplification product.
- the site that can be specifically cleaved in the DNA sample is preferably a restriction enzyme site.
- the restriction enzyme site those having a low frequency on the genome, for example, a Notl site are preferable.
- the arbitrary DNA to be added to the amplified product after the cleavage is not particularly limited, and for example, a polyA sequence can be suitably used.
- the length of the oligonucleotide bound to the substrate is generally from 5 bases to 200 bases, preferably from 10 bases to 130 bases, and more preferably from 15 bases to 100 bases.
- the immobilization of the oligonucleotide on the substrate can be performed chemically or non-chemically.
- An example of the chemical immobilization method is the carpoimide method (Japanese Patent Laid-Open No. 2000-146978), and a non-scientific immobilization method is the polylysine method (P. 0. Brown 5 s Lab .: http: : // cmgm.
- the hybridization reaction between the oligonucleotide on the substrate and the DNA sample should be performed, for example, under the conditions described in the Examples. It should be understood, however, that hybridization conditions are well known to those skilled in the art, and may vary with factors such as the length of the oligonucleotide.
- DNA hybridized to the oligonucleotide fragment immobilized on the substrate is detected by mass spectrometry (step (c)).
- the method of mass spectrometry is not particularly limited as long as the method can obtain an absolute molecular weight.
- MALDI-T0F MS is preferable.
- MALDI Microx Assisted Laser Desorption on Ionization
- the sample is placed in a state of being uniformly mixed with a large amount of matrix.
- TOF MS Time of Flight Mass Spectrometry
- MALDI-TOF MS is an ion flight based on the difference in the mass-to-charge ratio m / z when the ion charge is z and the ion mass is m. Mass spectrometry is performed using the difference in time.
- MALDI-TOF MS differs from other mass spectrometry methods such as GPC and LALLS, which determine the relative molecular weight, in that it has the characteristic of obtaining an absolute molecular weight.
- DNA samples for detection by MALDI-TOF MS do not necessarily require high-temperature (eg, 90 ° C) and quenching treatment of the duplex due to non-chemical bonding as a pretreatment. However, these pretreatments are preferred because they can increase sample sensitivity.
- an appropriate matrix solution is added to the DNA-hybridized substrate, and the DNA on the substrate is dried.
- the flight time differs depending on the molecular weight of the ionized sample (DNA hybridized to the oligonucleotide on the substrate), and the different flight times are detected as different peak positions.
- FIG. 1 is a diagram showing the results of 200 bp dsDNA (P (product) MALDI-TOFMS measurement using a gas plate.
- FIG. 2 is a diagram showing a hybridization signal when the oligonucleotide of SEQ ID NO: 1 was immobilized on a stainless steel plate as a substrate.
- FIG. 3 shows an oligonucleotide of SEQ ID NO: 2 immobilized on a stainless steel plate as a substrate.
- FIG. 4 is a diagram showing a hybridization signal when
- FIG. 4 is a diagram showing fixing of a cover glass to a sample slide which is a stainless steel plate.
- FIG. 5 is a diagram showing a hybridization signal when the oligonucleotide of SEQ ID NO: 4 or 5 (negative control) was immobilized on a glass plate.
- Example 1 200 bp dsDNA (PCR product) MALDI-T0FMS measurement using a glass plate
- reaction mixture (xl) used for PCR is as follows (() is for xlOO). ⁇ type ring A 10ng 1.
- PCR was performed using a Thermal cycler Cycle PE9700 (Applied Biosystems), followed by ⁇ 9 minutes at 95 ° C '', followed by ⁇ 45 seconds at 96 ° C, 45 seconds at 60 ° C, 1 minute at 72 ° C ''. Cycle, then "7 5 minutes at 2 ° C, termination at 4 ° C ”.
- the resulting PCR product was purified according to the QIAGEN MinElute PCR Purification kit protocol. 300 1 PCR product was passed through one column to elute d3 ⁇ 4010 il.
- Quantification was performed according to the PicoGreen dsDNA Quantitation kit (Molecular Probes) protocol.
- a slide glass (Code. # 000: 0.04 mm thick) was fixed on a stainless steel plate (sample slide) with double-sided tape.
- the matrix and sample were mixed 1: 1 and spotted 0.5-1 onto glass.
- the sample slide was air dried (crystallized) and then introduced into a mass spectrometer for measurement.
- KRAT0S K0MPACT MALDI 4 The measurement was performed using KRAT0S K0MPACT MALDI 4 (Shimadzu). The measurement conditions of K0MPACT MALDI 4 are shown below. Three
- a stainless steel plate (stainless steel plate; manufactured by KRATOS ANALYTICAL Co., Ltd.) was calposimidated according to the method of JP-A-2000-146978.
- An oligonucleotide having the nucleotide sequence represented by SEQ ID NO: 1 (calculated value; molecular weight: 7583) and SEQ ID NO: 2 (calculated value: molecular weight: 7638) was dissolved in a buffer to give 100 pmol / zl to prepare an MA solution. .
- the DNA solution was spotted at a predetermined position on a stainless steel plate for carpoimidization.
- buffer A 0.2 M sodium chloride, 0.1 M Tris-HCl (pH 7.5) containing 3% BSA (pserum albumin), 0.05% X-100
- BSA pserum albumin
- X-100 0.05% X-100
- a hybridization solution [5 X SSC (SSC: 1.5 M NaCl, 0.15 M sodium citrate), 10% dextran, SEQ ID NO: 3 (calculated value; molecular weight) 6190) Probe] 25 ⁇ 1 was placed and heated 1 ⁇ in a 40 ° C water bath.
- the hybridization solution was lightly sucked from the carbodiimidated stainless steel plate, and subjected to post-hybridization washing to remove non-specifically adsorbed probes.
- the post-hybridization washing conditions were as follows: (I) 2 x SSC 0.1% SDS; 5 minutes at room temperature twice, (ii) 0.2 X SSC, 0.1% SDS; 40 ° C, 5 minutes twice, (Iii) 2 ⁇ SSC; room temperature, 5 minutes, (iv) 0.3 M aqueous ammonium citrate solution; room temperature, 15 seconds.
- the obtained carbodimidized stainless steel plate was measured using KOMPACT MALDI2 (manufactured by Shimadzu Corporation). The results are shown in FIGS. 2 and 3.
- the probe nucleic acid can be specifically obtained as a very clear signal (actually measured value; at a position of molecular weight 6185). On the other hand, no signal could be detected from the spot of SEQ ID NO: 2.
- Cover glass # 000 (manufactured by Matsunami Glass Co., Ltd.) was carbodimidated according to the method of JP-A-2000-146978. Oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 4 (Capture oligomer) and SEQ ID NO: 5 (negative control) were dissolved in a buffer to lZOpmol / 1 to obtain a DNA solution. The DNA solution and the buffer were spotted at predetermined positions on a carbodimidated cover glass using a Pittman at a predetermined position.
- the cells were immersed in buffer A (0.2 M sodium chloride, 0.1 M and sulphate hydrochloride (pH 7.5), 0.05% Triton X-100) containing 3% BSA (pserum albumin). And dried at 37 ° C for 15 minutes.
- buffer A 0.2 M sodium chloride, 0.1 M and sulphate hydrochloride (pH 7.5), 0.05% Triton X-100
- BSA pserum albumin
- the calposimidated cover glass was washed with a TE buffer (10 mM and ris hydrochloric acid (pH 7.2) / lmM EDTA), and dried at 37 ° C. for 15 minutes. No oligonucleotide (DNA (-)) was also used as a control.
- a probe of the hybridization solution [5 X SSC (SSC: 1.5 M NaCK 0.15 M sodium citrate), 10% dextran, SEQ ID NO: 6 or SEQ ID NO: 7] was placed on the DNA-fixed portion of the carbodimidated cover glass. ] Place 10 ⁇ 1 and heat it for 1 ⁇ with a dryer at 30 ° C.
- the hybridization solution was gently sucked from the carbodimidated cover glass, and subjected to post-hybridization washing under the following conditions.
- the washing conditions for the post hybridization were (I) 2 ⁇ SSC; room temperature for 5 minutes, (ii) 0.3 M aqueous ammonium citrate solution; room temperature for 15 seconds.
- Pridine-2-carboxylic acid (3-Hydroxy-2-pico 1 inic acid): Mw.139.11 0.7M3 ⁇ 40.0974g
- Di ammonium Hydrogen citrate Mw.226.2 0.07M was dissolved in 0.010583g and prepared.
- KOMPACT MALDI 4 The measurement conditions of KOMPACT MALDI 4 are shown below.
- Laser power 150 50mer
- 180 180 (lOOmer)
- the present invention provides a method capable of efficiently detecting a genetic polymorphism using a mass spectrometer, thereby enabling rapid and comprehensive detection of a genetic polymorphism in multiple samples.
- the method of the present invention can greatly contribute to disease correlation analysis ⁇ gene diagnosis for determining a polymorphism that causes a specific disease.
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002222614A AU2002222614A1 (en) | 2000-12-12 | 2001-12-12 | Method of detecting polymorphism in dna by using mass spectroscopy |
JP2002551186A JPWO2002050307A1 (ja) | 2000-12-12 | 2001-12-12 | 質量分析を利用してdnaの多型を検出する方法 |
US10/450,761 US20040248098A1 (en) | 2000-12-12 | 2001-12-12 | Method of detecting polymorphisms in dna by using mass spectroscopy |
EP01271113A EP1350851A4 (en) | 2000-12-12 | 2001-12-12 | METHOD FOR DETECTION OF POLYMORPHISM IN DNA BY MEANS OF MASS SPECTROSCOPY |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-378091 | 2000-12-12 | ||
JP2000378091 | 2000-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002050307A1 true WO2002050307A1 (fr) | 2002-06-27 |
Family
ID=18846720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010892 WO2002050307A1 (fr) | 2000-12-12 | 2001-12-12 | Procede de detection de polymorphisme dans l'adn au moyen d'une spectroscopie de masse |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040248098A1 (ja) |
EP (1) | EP1350851A4 (ja) |
JP (1) | JPWO2002050307A1 (ja) |
AU (1) | AU2002222614A1 (ja) |
WO (1) | WO2002050307A1 (ja) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1405923A2 (en) * | 2002-09-28 | 2004-04-07 | Hidetoshi Dr. Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
JP2005245362A (ja) * | 2004-03-05 | 2005-09-15 | Kyowa Medex Co Ltd | 肺癌および頭頸部癌の発症危険率を予測する方法 |
JP2006521812A (ja) * | 2003-03-18 | 2006-09-28 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
US7510834B2 (en) | 2000-04-13 | 2009-03-31 | Hidetoshi Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
JP2009520460A (ja) * | 2003-03-10 | 2009-05-28 | アプレラ コーポレイション | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 |
JP2009521904A (ja) * | 2003-03-10 | 2009-06-11 | アプレラ コーポレイション | 狭窄に関連する一塩基多型、その検出方法および使用 |
JP2009523404A (ja) * | 2003-01-30 | 2009-06-25 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
US8088582B2 (en) | 2006-04-06 | 2012-01-03 | Ibis Biosciences, Inc. | Compositions for the use in identification of fungi |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8158936B2 (en) | 2009-02-12 | 2012-04-17 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US8173957B2 (en) | 2004-05-24 | 2012-05-08 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8182992B2 (en) | 2005-03-03 | 2012-05-22 | Ibis Biosciences, Inc. | Compositions for use in identification of adventitious viruses |
US8187814B2 (en) | 2004-02-18 | 2012-05-29 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US8214154B2 (en) | 2001-03-02 | 2012-07-03 | Ibis Biosciences, Inc. | Systems for rapid identification of pathogens in humans and animals |
US8265878B2 (en) | 2001-03-02 | 2012-09-11 | Ibis Bioscience, Inc. | Method for rapid detection and identification of bioagents |
US8268565B2 (en) | 2001-03-02 | 2012-09-18 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US8298760B2 (en) | 2001-06-26 | 2012-10-30 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8407010B2 (en) | 2004-05-25 | 2013-03-26 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA |
US8534447B2 (en) | 2008-09-16 | 2013-09-17 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8550694B2 (en) | 2008-09-16 | 2013-10-08 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, systems, and methods |
US8551738B2 (en) | 2005-07-21 | 2013-10-08 | Ibis Biosciences, Inc. | Systems and methods for rapid identification of nucleic acid variants |
US8563250B2 (en) | 2001-03-02 | 2013-10-22 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US8822156B2 (en) | 2002-12-06 | 2014-09-02 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8871471B2 (en) | 2007-02-23 | 2014-10-28 | Ibis Biosciences, Inc. | Methods for rapid forensic DNA analysis |
US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
US9080209B2 (en) | 2009-08-06 | 2015-07-14 | Ibis Biosciences, Inc. | Non-mass determined base compositions for nucleic acid detection |
US9149473B2 (en) | 2006-09-14 | 2015-10-06 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
US9194877B2 (en) | 2009-07-17 | 2015-11-24 | Ibis Biosciences, Inc. | Systems for bioagent indentification |
US9393564B2 (en) | 2009-03-30 | 2016-07-19 | Ibis Biosciences, Inc. | Bioagent detection systems, devices, and methods |
US9416409B2 (en) | 2009-07-31 | 2016-08-16 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
US9719083B2 (en) | 2009-03-08 | 2017-08-01 | Ibis Biosciences, Inc. | Bioagent detection methods |
US9758840B2 (en) | 2010-03-14 | 2017-09-12 | Ibis Biosciences, Inc. | Parasite detection via endosymbiont detection |
US9873906B2 (en) | 2004-07-14 | 2018-01-23 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
US9890408B2 (en) | 2009-10-15 | 2018-02-13 | Ibis Biosciences, Inc. | Multiple displacement amplification |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652514A (zh) * | 2019-02-25 | 2019-04-19 | 北京市理化分析测试中心 | 一种CYP3A5基因rs776746位点多态性核酸质谱检测方法 |
CN114317680A (zh) * | 2021-12-25 | 2022-04-12 | 广州禾信康源医疗科技有限公司 | 基质溶液和基质辅助激光解吸电离飞行时间质谱检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029431A2 (en) * | 1995-03-17 | 1996-09-26 | Sequenom, Inc. | Dna diagnostics based on mass spectrometry |
EP1026259A1 (en) * | 1999-02-08 | 2000-08-09 | Fuji Photo Film Co., Ltd. | Dna chip and its preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821060A (en) * | 1996-08-02 | 1998-10-13 | Atom Sciences, Inc. | DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA |
ATE374836T1 (de) * | 1997-01-15 | 2007-10-15 | Xzillion Gmbh & Co Kg | Massenmarkierte hybridisierungssonden |
WO1999014375A2 (en) * | 1997-09-19 | 1999-03-25 | Genetrace Systems, Inc. | Dna typing by mass spectrometry with polymorphic dna repeat markers |
US7014994B1 (en) * | 1999-03-19 | 2006-03-21 | Cornell Research Foundation,Inc. | Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process |
-
2001
- 2001-12-12 JP JP2002551186A patent/JPWO2002050307A1/ja active Pending
- 2001-12-12 US US10/450,761 patent/US20040248098A1/en not_active Abandoned
- 2001-12-12 WO PCT/JP2001/010892 patent/WO2002050307A1/ja active Application Filing
- 2001-12-12 AU AU2002222614A patent/AU2002222614A1/en not_active Abandoned
- 2001-12-12 EP EP01271113A patent/EP1350851A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996029431A2 (en) * | 1995-03-17 | 1996-09-26 | Sequenom, Inc. | Dna diagnostics based on mass spectrometry |
EP1026259A1 (en) * | 1999-02-08 | 2000-08-09 | Fuji Photo Film Co., Ltd. | Dna chip and its preparation |
Non-Patent Citations (4)
Title |
---|
DAVID G. WANG ET AL.: "Large scale identification, mapping and genotyping of single-nucleotide polymorphisms in the human genome", SCIENCE, vol. 280, no. 5366, May 1998 (1998-05-01), pages 1077 - 1082, XP002089398 * |
KAI TANG ET AL.: "Chip-based genotyping by mass spectrometry", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 18, August 1999 (1999-08-01), pages 10016 - 10020, XP002909309 * |
OSAMU NOMURA ET AL.: "Genome kinou kenkyu", YODOSHA CO., LTD., 10 April 2000 (2000-04-10), pages 138 - 149, XP002909310 * |
See also references of EP1350851A4 * |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7510834B2 (en) | 2000-04-13 | 2009-03-31 | Hidetoshi Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
US8268565B2 (en) | 2001-03-02 | 2012-09-18 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US8214154B2 (en) | 2001-03-02 | 2012-07-03 | Ibis Biosciences, Inc. | Systems for rapid identification of pathogens in humans and animals |
US9416424B2 (en) | 2001-03-02 | 2016-08-16 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US9752184B2 (en) | 2001-03-02 | 2017-09-05 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US8265878B2 (en) | 2001-03-02 | 2012-09-11 | Ibis Bioscience, Inc. | Method for rapid detection and identification of bioagents |
US8815513B2 (en) | 2001-03-02 | 2014-08-26 | Ibis Biosciences, Inc. | Method for rapid detection and identification of bioagents in epidemiological and forensic investigations |
US8802372B2 (en) | 2001-03-02 | 2014-08-12 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US8563250B2 (en) | 2001-03-02 | 2013-10-22 | Ibis Biosciences, Inc. | Methods for identifying bioagents |
US8921047B2 (en) | 2001-06-26 | 2014-12-30 | Ibis Biosciences, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8298760B2 (en) | 2001-06-26 | 2012-10-30 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
US8380442B2 (en) | 2001-06-26 | 2013-02-19 | Ibis Bioscience, Inc. | Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby |
EP2019148A1 (en) * | 2002-09-28 | 2009-01-28 | Inoko, Hidetoshi, Dr. | Gene mapping method using microsatellite genetic polymorphism markers |
EP1405923A2 (en) * | 2002-09-28 | 2004-04-07 | Hidetoshi Dr. Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
EP1405923A3 (en) * | 2002-09-28 | 2004-06-30 | Hidetoshi Dr. Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
US9725771B2 (en) | 2002-12-06 | 2017-08-08 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8822156B2 (en) | 2002-12-06 | 2014-09-02 | Ibis Biosciences, Inc. | Methods for rapid identification of pathogens in humans and animals |
JP2009523404A (ja) * | 2003-01-30 | 2009-06-25 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
JP2009520460A (ja) * | 2003-03-10 | 2009-05-28 | アプレラ コーポレイション | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 |
JP2009521904A (ja) * | 2003-03-10 | 2009-06-11 | アプレラ コーポレイション | 狭窄に関連する一塩基多型、その検出方法および使用 |
JP2006521812A (ja) * | 2003-03-18 | 2006-09-28 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8476415B2 (en) | 2003-05-13 | 2013-07-02 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US8242254B2 (en) | 2003-09-11 | 2012-08-14 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8013142B2 (en) | 2003-09-11 | 2011-09-06 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8288523B2 (en) | 2003-09-11 | 2012-10-16 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8394945B2 (en) | 2003-09-11 | 2013-03-12 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8163895B2 (en) | 2003-12-05 | 2012-04-24 | Ibis Biosciences, Inc. | Compositions for use in identification of orthopoxviruses |
US9447462B2 (en) | 2004-02-18 | 2016-09-20 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US8187814B2 (en) | 2004-02-18 | 2012-05-29 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
JP2005245362A (ja) * | 2004-03-05 | 2005-09-15 | Kyowa Medex Co Ltd | 肺癌および頭頸部癌の発症危険率を予測する方法 |
US8987660B2 (en) | 2004-05-24 | 2015-03-24 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US9449802B2 (en) | 2004-05-24 | 2016-09-20 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8173957B2 (en) | 2004-05-24 | 2012-05-08 | Ibis Biosciences, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US8407010B2 (en) | 2004-05-25 | 2013-03-26 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA |
US9873906B2 (en) | 2004-07-14 | 2018-01-23 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
US8182992B2 (en) | 2005-03-03 | 2012-05-22 | Ibis Biosciences, Inc. | Compositions for use in identification of adventitious viruses |
US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
US8551738B2 (en) | 2005-07-21 | 2013-10-08 | Ibis Biosciences, Inc. | Systems and methods for rapid identification of nucleic acid variants |
US8088582B2 (en) | 2006-04-06 | 2012-01-03 | Ibis Biosciences, Inc. | Compositions for the use in identification of fungi |
US9149473B2 (en) | 2006-09-14 | 2015-10-06 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
US8871471B2 (en) | 2007-02-23 | 2014-10-28 | Ibis Biosciences, Inc. | Methods for rapid forensic DNA analysis |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US9027730B2 (en) | 2008-09-16 | 2015-05-12 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US8252599B2 (en) | 2008-09-16 | 2012-08-28 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US9023655B2 (en) | 2008-09-16 | 2015-05-05 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8534447B2 (en) | 2008-09-16 | 2013-09-17 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
US8550694B2 (en) | 2008-09-16 | 2013-10-08 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, systems, and methods |
US8609430B2 (en) | 2008-09-16 | 2013-12-17 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8796617B2 (en) | 2009-02-12 | 2014-08-05 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US9165740B2 (en) | 2009-02-12 | 2015-10-20 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US8158936B2 (en) | 2009-02-12 | 2012-04-17 | Ibis Biosciences, Inc. | Ionization probe assemblies |
US9719083B2 (en) | 2009-03-08 | 2017-08-01 | Ibis Biosciences, Inc. | Bioagent detection methods |
US9393564B2 (en) | 2009-03-30 | 2016-07-19 | Ibis Biosciences, Inc. | Bioagent detection systems, devices, and methods |
US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
US9194877B2 (en) | 2009-07-17 | 2015-11-24 | Ibis Biosciences, Inc. | Systems for bioagent indentification |
US9416409B2 (en) | 2009-07-31 | 2016-08-16 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
US10119164B2 (en) | 2009-07-31 | 2018-11-06 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
US9080209B2 (en) | 2009-08-06 | 2015-07-14 | Ibis Biosciences, Inc. | Non-mass determined base compositions for nucleic acid detection |
US9890408B2 (en) | 2009-10-15 | 2018-02-13 | Ibis Biosciences, Inc. | Multiple displacement amplification |
US9758840B2 (en) | 2010-03-14 | 2017-09-12 | Ibis Biosciences, Inc. | Parasite detection via endosymbiont detection |
Also Published As
Publication number | Publication date |
---|---|
US20040248098A1 (en) | 2004-12-09 |
EP1350851A4 (en) | 2007-07-11 |
EP1350851A1 (en) | 2003-10-08 |
JPWO2002050307A1 (ja) | 2004-04-22 |
AU2002222614A1 (en) | 2002-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002050307A1 (fr) | Procede de detection de polymorphisme dans l'adn au moyen d'une spectroscopie de masse | |
Griffin et al. | Single-nucleotide polymorphism analysis by MALDI–TOF mass spectrometry | |
JP4498657B2 (ja) | Dnaサンプル中のシトシン−メチル化とsnp又は突然変異の同時検出方法 | |
Hartmer et al. | RNase T1 mediated base‐specific cleavage and MALDI‐TOF MS for high‐throughput comparative sequence analysis | |
JP5382802B2 (ja) | 質量分析法を用いた生体分子の検出および定量 | |
JP2003523752A (ja) | Dnaプローブにおいてシトシンのメチル化を検出するリガーゼ/ポリメラーゼ法 | |
JP2001505045A (ja) | 質量決定による核酸検出方法 | |
JP2004535815A (ja) | ニック形成剤を用いた核酸フラグメントの増幅 | |
EP1885890A2 (en) | Quantification of nucleic acids and proteins using oligonucleotide mass tags | |
WO2009073251A1 (en) | Detection and quantification of biomolecules using mass spectrometry | |
JP4564219B2 (ja) | Dna−プローブの中のシトシン−メチル化の検出方法 | |
AU757473B2 (en) | Method for identifying cytosine methylation patterns in genomic DNA | |
EP1047794A2 (en) | Method for the detection or nucleic acid of nucleic acid sequences | |
US20070161036A1 (en) | Method for distinguishing 5-position methylation changes of cytosine bases and cytosine-to-thymine mutations and for detecting single nucleotide polymorphisms (SNPs) or point mutations in genomic DNA | |
WO2002018659A2 (en) | Method for determining alleles | |
US7008770B1 (en) | Method for the controlled implementation of complex PCR amplifications | |
EP1488003A1 (en) | Method for the analysis of methylation patterns within nucleic acids by means of mass spectrometry | |
JP2007532120A (ja) | 核酸分子のサブセットを選択的に検出するための方法 | |
EP1303638B1 (en) | Method for haplotyping by mass spectrometry | |
US20050202420A1 (en) | Oligonucleotides or pna oligomers and a method for detecting the methylation state of genomic dna in a parallel manner | |
US20060166201A1 (en) | Method for the detection of nucleic acid sequences by means of crackable probe molecules | |
JP4550416B2 (ja) | 核酸の配列決定方法 | |
JP2003093075A (ja) | 電気抵抗を利用した核酸変異検出法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002551186 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001271113 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001271113 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10450761 Country of ref document: US |